Janine Lombard

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

Halle C. F. Moore, Joseph M. Unger, Kelly‐Anne Phillips et al. · New England Journal of Medicine · 2015 · 530 citations · Full text

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Yoland Antill, Peey‐Sei Kok, Kristy Robledo et al. · Journal for ImmunoTherapy of Cancer · 2021 · 120 citations · Full text

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Cristina Saura, Dominik Hlauschek, Mafalda Oliveira et al. · The Lancet Oncology · 2019 · 95 citations

Breast Oncology, Endocrine-related Cancer, Taselisib Versus +11

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230

Halle C. F. Moore, Joseph M. Unger, Kelly‐Anne Phillips et al. · JNCI Journal of the National Cancer Institute · 2018 · 89 citations · Full text

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

Nicoletta Colombo, Elena Biagioli, Kenichi Harano et al. · The Lancet Oncology · 2024 · 89 citations

Gynecological Surgery, Medicine, Metronomic Therapy +6